SE513082C2 - Användning av taxol i infusionspreparat - Google Patents

Användning av taxol i infusionspreparat

Info

Publication number: SE513082C2
Authority: SE; Sweden
Prior art keywords: taxol; infusion; patients; treatment; hours
Prior art date: 1992-08-03

Application number

SE9301951A

Other languages

English (en)

Swedish (sv)

Other versions

SE9301951D0 (sv

SE9301951L (sv

Inventor

Renzo M Canetta

Marcel Rozencweig

Elizabeth Eisenhauer

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-08-03

Filing date

1993-06-08

Publication date

2000-07-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25448992&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE513082(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1993-06-08 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

1993-06-08 Publication of SE9301951D0 publication Critical patent/SE9301951D0/xx

1994-02-07 Publication of SE9301951L publication Critical patent/SE9301951L/xx

2000-07-03 Publication of SE513082C2 publication Critical patent/SE513082C2/sv

Links

229930012538 Paclitaxel Natural products 0.000 title claims abstract description 157
229960001592 paclitaxel Drugs 0.000 title claims abstract description 157
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title claims abstract description 157
238000001802 infusion Methods 0.000 title claims description 133
238000002360 preparation method Methods 0.000 title claims 2
238000011282 treatment Methods 0.000 claims abstract description 57
238000011275 oncology therapy Methods 0.000 claims abstract 3
206010033128 Ovarian cancer Diseases 0.000 claims description 14
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 10
239000000739 antihistaminic agent Substances 0.000 claims description 9
ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 claims description 9
230000009467 reduction Effects 0.000 claims description 9
229960000520 diphenhydramine Drugs 0.000 claims description 8
206010061535 Ovarian neoplasm Diseases 0.000 claims description 7
229960003957 dexamethasone Drugs 0.000 claims description 7
UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims description 7
150000003431 steroids Chemical class 0.000 claims description 7
208000003455 anaphylaxis Diseases 0.000 claims description 6
229940125715 antihistaminic agent Drugs 0.000 claims description 6
229960003291 chlorphenamine Drugs 0.000 claims description 6
229960000890 hydrocortisone Drugs 0.000 claims description 5
231100000228 neurotoxicity Toxicity 0.000 claims description 5
230000007135 neurotoxicity Effects 0.000 claims description 5
206010029350 Neurotoxicity Diseases 0.000 claims description 4
206010044221 Toxic encephalopathy Diseases 0.000 claims description 4
239000003795 chemical substances by application Substances 0.000 claims description 4
DBAKFASWICGISY-BTJKTKAUSA-N Chlorpheniramine maleate Chemical compound OC(=O)\C=C/C(O)=O.C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 DBAKFASWICGISY-BTJKTKAUSA-N 0.000 claims description 3
SOYKEARSMXGVTM-UHFFFAOYSA-N chlorphenamine Chemical compound C=1C=CC=NC=1C(CCN(C)C)C1=CC=C(Cl)C=C1 SOYKEARSMXGVTM-UHFFFAOYSA-N 0.000 claims description 3
-1 cixnetidine Chemical compound 0.000 claims description 3
230000002093 peripheral effect Effects 0.000 claims description 3
229960004618 prednisone Drugs 0.000 claims description 3
XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 claims description 3
229940044551 receptor antagonist Drugs 0.000 claims description 3
239000002464 receptor antagonist Substances 0.000 claims description 3
SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 claims description 2
206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
229960002881 clemastine Drugs 0.000 claims description 2
YNNUSGIPVFPVBX-NHCUHLMSSA-N clemastine Chemical compound CN1CCC[C@@H]1CCO[C@@](C)(C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 YNNUSGIPVFPVBX-NHCUHLMSSA-N 0.000 claims description 2
229940099401 dimethindene maleate Drugs 0.000 claims description 2
229960001596 famotidine Drugs 0.000 claims description 2
XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 claims description 2
201000005202 lung cancer Diseases 0.000 claims description 2
208000020816 lung neoplasm Diseases 0.000 claims description 2
150000001875 compounds Chemical class 0.000 claims 3
206010009944 Colon cancer Diseases 0.000 claims 1
210000001072 colon Anatomy 0.000 claims 1
208000029742 colonic neoplasm Diseases 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
230000002611 ovarian Effects 0.000 claims 1
206010028980 Neoplasm Diseases 0.000 abstract description 19
238000006243 chemical reaction Methods 0.000 abstract description 10
229940079593 drug Drugs 0.000 abstract description 6
239000003814 drug Substances 0.000 abstract description 6
238000002483 medication Methods 0.000 abstract 1
206010020751 Hypersensitivity Diseases 0.000 description 59
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 26
238000009101 premedication Methods 0.000 description 23
238000000034 method Methods 0.000 description 16
230000004044 response Effects 0.000 description 16
201000011510 cancer Diseases 0.000 description 15
OKEKLOJNCOIPIT-ZCOVNTAASA-N taxoline Chemical compound O([C@@H]1[C@]2(O)C[C@@H](C(=C([C@@H](OC(C)=O)C(=O)[C@]3(C)[C@H](O)C[C@H]4OC[C@]4([C@H]31)OC(C)=O)C2(C)C)C)OC(=O)[C@H](O)[C@@H](NC(=O)C(C)CC)C=1C=CC=CC=1)C(=O)C1=CC=CC=C1 OKEKLOJNCOIPIT-ZCOVNTAASA-N 0.000 description 14
229910052697 platinum Inorganic materials 0.000 description 13
208000024891 symptom Diseases 0.000 description 13
208000004235 neutropenia Diseases 0.000 description 11
208000033808 peripheral neuropathy Diseases 0.000 description 11
210000004027 cell Anatomy 0.000 description 10
231100000419 toxicity Toxicity 0.000 description 10
230000001988 toxicity Effects 0.000 description 10
238000002560 therapeutic procedure Methods 0.000 description 9
210000001772 blood platelet Anatomy 0.000 description 8
206010013975 Dyspnoeas Diseases 0.000 description 7
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 7
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 7
230000000118 anti-neoplastic effect Effects 0.000 description 7
230000000694 effects Effects 0.000 description 7
206010037844 rash Diseases 0.000 description 7
208000010201 Exanthema Diseases 0.000 description 6
208000032843 Hemorrhage Diseases 0.000 description 6
201000010099 disease Diseases 0.000 description 6
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
201000005884 exanthem Diseases 0.000 description 6
210000003714 granulocyte Anatomy 0.000 description 6
239000008389 polyethoxylated castor oil Substances 0.000 description 6
UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 5
229930182837 (R)-adrenaline Natural products 0.000 description 5
206010065553 Bone marrow failure Diseases 0.000 description 5
229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 5
230000001154 acute effect Effects 0.000 description 5
208000006218 bradycardia Diseases 0.000 description 5
229960005139 epinephrine Drugs 0.000 description 5
210000000265 leukocyte Anatomy 0.000 description 5
201000002364 leukopenia Diseases 0.000 description 5
231100001022 leukopenia Toxicity 0.000 description 5
230000007823 neuropathy Effects 0.000 description 5
201000001119 neuropathy Diseases 0.000 description 5
229960000620 ranitidine Drugs 0.000 description 5
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 5
208000001953 Hypotension Diseases 0.000 description 4
206010028813 Nausea Diseases 0.000 description 4
230000002411 adverse Effects 0.000 description 4
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 4
230000036543 hypotension Effects 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
230000002045 lasting effect Effects 0.000 description 4
230000007774 longterm Effects 0.000 description 4
230000008693 nausea Effects 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
102000007644 Colony-Stimulating Factors Human genes 0.000 description 3
108010071942 Colony-Stimulating Factors Proteins 0.000 description 3
208000000059 Dyspnea Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 3
208000024780 Urticaria Diseases 0.000 description 3
230000001387 anti-histamine Effects 0.000 description 3
230000036772 blood pressure Effects 0.000 description 3
210000001185 bone marrow Anatomy 0.000 description 3
230000036471 bradycardia Effects 0.000 description 3
210000001175 cerebrospinal fluid Anatomy 0.000 description 3
229960001380 cimetidine Drugs 0.000 description 3
CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 3
229940047120 colony stimulating factors Drugs 0.000 description 3
229960000935 dehydrated alcohol Drugs 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
230000002489 hematologic effect Effects 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000011084 recovery Methods 0.000 description 3
206010002199 Anaphylactic shock Diseases 0.000 description 2
BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
206010049765 Bradyarrhythmia Diseases 0.000 description 2
206010055113 Breast cancer metastatic Diseases 0.000 description 2
208000002633 Febrile Neutropenia Diseases 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
102000001554 Hemoglobins Human genes 0.000 description 2
108010054147 Hemoglobins Proteins 0.000 description 2
208000001871 Tachycardia Diseases 0.000 description 2
206010047700 Vomiting Diseases 0.000 description 2
UCTWMZQNUQWSLP-UHFFFAOYSA-N adrenaline Chemical compound CNCC(O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-UHFFFAOYSA-N 0.000 description 2
208000030961 allergic reaction Diseases 0.000 description 2
208000007502 anemia Diseases 0.000 description 2
238000004820 blood count Methods 0.000 description 2
238000002512 chemotherapy Methods 0.000 description 2
238000009104 chemotherapy regimen Methods 0.000 description 2
229940109239 creatinine Drugs 0.000 description 2
239000008121 dextrose Substances 0.000 description 2
230000009429 distress Effects 0.000 description 2
239000012530 fluid Substances 0.000 description 2
231100000226 haematotoxicity Toxicity 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000000977 initiatory effect Effects 0.000 description 2
230000003907 kidney function Effects 0.000 description 2
230000003908 liver function Effects 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
230000000306 recurrent effect Effects 0.000 description 2
238000011268 retreatment Methods 0.000 description 2
210000002966 serum Anatomy 0.000 description 2
208000013220 shortness of breath Diseases 0.000 description 2
238000011105 stabilization Methods 0.000 description 2
230000006794 tachycardia Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
238000011269 treatment regimen Methods 0.000 description 2
230000008673 vomiting Effects 0.000 description 2
VHRSUDSXCMQTMA-PJHHCJLFSA-N 6alpha-methylprednisolone Chemical compound C([C@@]12C)=CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2[C@@H](O)C[C@]2(C)[C@@](O)(C(=O)CO)CC[C@H]21 VHRSUDSXCMQTMA-PJHHCJLFSA-N 0.000 description 1
206010000087 Abdominal pain upper Diseases 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
201000004384 Alopecia Diseases 0.000 description 1
208000028185 Angioedema Diseases 0.000 description 1
PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
206010003130 Arrhythmia supraventricular Diseases 0.000 description 1
102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
208000026310 Breast neoplasm Diseases 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
241000282693 Cercopithecidae Species 0.000 description 1
208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
206010015856 Extrasystoles Diseases 0.000 description 1
206010019233 Headaches Diseases 0.000 description 1
208000010496 Heart Arrest Diseases 0.000 description 1
206010019280 Heart failures Diseases 0.000 description 1
208000033830 Hot Flashes Diseases 0.000 description 1
206010060800 Hot flush Diseases 0.000 description 1
208000008454 Hyperhidrosis Diseases 0.000 description 1
206010020772 Hypertension Diseases 0.000 description 1
PWWVAXIEGOYWEE-UHFFFAOYSA-N Isophenergan Chemical compound C1=CC=C2N(CC(C)N(C)C)C3=CC=CC=C3SC2=C1 PWWVAXIEGOYWEE-UHFFFAOYSA-N 0.000 description 1
206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
206010050513 Metastatic renal cell carcinoma Diseases 0.000 description 1
229930192392 Mitomycin Natural products 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
201000010927 Mucositis Diseases 0.000 description 1
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 1
206010028817 Nausea and vomiting symptoms Diseases 0.000 description 1
SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
239000000006 Nitroglycerin Substances 0.000 description 1
208000025047 Non-histaminic angioedema Diseases 0.000 description 1
229920002685 Polyoxyl 35CastorOil Polymers 0.000 description 1
208000000418 Premature Cardiac Complexes Diseases 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
208000037656 Respiratory Sounds Diseases 0.000 description 1
206010040738 Sinus arrest Diseases 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
238000008050 Total Bilirubin Reagent Methods 0.000 description 1
208000025865 Ulcer Diseases 0.000 description 1
208000009729 Ventricular Premature Complexes Diseases 0.000 description 1
206010047281 Ventricular arrhythmia Diseases 0.000 description 1
206010047289 Ventricular extrasystoles Diseases 0.000 description 1
206010047924 Wheezing Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
208000009956 adenocarcinoma Diseases 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
208000026935 allergic disease Diseases 0.000 description 1
230000007815 allergy Effects 0.000 description 1
231100000360 alopecia Toxicity 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003474 anti-emetic effect Effects 0.000 description 1
230000000259 anti-tumor effect Effects 0.000 description 1
239000002111 antiemetic agent Substances 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
230000001746 atrial effect Effects 0.000 description 1
229940088007 benadryl Drugs 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
230000000740 bleeding effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
230000007883 bronchodilation Effects 0.000 description 1
190000008236 carboplatin Chemical compound 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
230000008859 change Effects 0.000 description 1
230000000052 comparative effect Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
208000013219 diaphoresis Diseases 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
231100000371 dose-limiting toxicity Toxicity 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
229940124645 emergency medicine Drugs 0.000 description 1
208000037828 epithelial carcinoma Diseases 0.000 description 1
208000030533 eye disease Diseases 0.000 description 1
208000011318 facial edema Diseases 0.000 description 1
238000001914 filtration Methods 0.000 description 1
230000006870 function Effects 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000011521 glass Substances 0.000 description 1
229960003711 glyceryl trinitrate Drugs 0.000 description 1
231100000869 headache Toxicity 0.000 description 1
230000036541 health Effects 0.000 description 1
239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
230000006872 improvement Effects 0.000 description 1
208000003243 intestinal obstruction Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
208000021039 metastatic melanoma Diseases 0.000 description 1
229960004584 methylprednisolone Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
230000008520 organization Effects 0.000 description 1
QUANRIQJNFHVEU-UHFFFAOYSA-N oxirane;propane-1,2,3-triol Chemical compound C1CO1.OCC(O)CO QUANRIQJNFHVEU-UHFFFAOYSA-N 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
208000035824 paresthesia Diseases 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
229920000098 polyolefin Polymers 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
239000011148 porous material Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000009117 preventive therapy Methods 0.000 description 1
229960003910 promethazine Drugs 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
229960002052 salbutamol Drugs 0.000 description 1
231100000004 severe toxicity Toxicity 0.000 description 1
231100000046 skin rash Toxicity 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
229930184616 taxin Natural products 0.000 description 1
KOTXAHKUCAQPQA-AAUVPWARSA-N taxine Chemical compound C1([C@@H]([C@@H](O)C(=O)O[C@@H]2C=3/C[C@@](C([C@H](O)C4=C(C)[C@@H](OC(C)=O)CC(C4(C)C)[C@@H](OC(C)=O)\C=3)=O)(C)[C@@H](O)C2)N(C)C)=CC=CC=C1 KOTXAHKUCAQPQA-AAUVPWARSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
206010043554 thrombocytopenia Diseases 0.000 description 1
231100000816 toxic dose Toxicity 0.000 description 1
231100000155 toxicity by organ Toxicity 0.000 description 1
230000007675 toxicity by organ Effects 0.000 description 1
230000036269 ulceration Effects 0.000 description 1
231100000402 unacceptable toxicity Toxicity 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Oncology (AREA)
Hematology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Epoxy Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)

SE9301951A 1992-08-03 1993-06-08 Användning av taxol i infusionspreparat SE513082C2 (sv)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US92362892A	1992-08-03	1992-08-03

Publications (3)

Publication Number	Publication Date
SE9301951D0 SE9301951D0 (sv)	1993-06-08
SE9301951L SE9301951L (sv)	1994-02-07
SE513082C2 true SE513082C2 (sv)	2000-07-03

Family

ID=25448992

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9301951A SE513082C2 (sv)	1992-08-03	1993-06-08	Användning av taxol i infusionspreparat

Country Status (23)

Country	Link
US (5)	US5641803A (fr)
EP (3)	EP0783885A3 (fr)
JP (1)	JP2848760B2 (fr)
AT (1)	ATE152910T1 (fr)
AU (3)	AU3216893A (fr)
BE (1)	BE1006497A5 (fr)
CA (1)	CA2086874E (fr)
CH (1)	CH686868A5 (fr)
DE (2)	DE69310634T2 (fr)
DK (2)	DK65293A (fr)
ES (2)	ES2105926B1 (fr)
FR (1)	FR2694192B1 (fr)
GB (1)	GB9311740D0 (fr)
GR (2)	GR1001617B (fr)
IE (1)	IE80620B1 (fr)
IL (1)	IL105879A (fr)
IT (1)	IT1276041B1 (fr)
MY (1)	MY109862A (fr)
NL (1)	NL9301086A (fr)
NZ (1)	NZ245795A (fr)
PT (1)	PT101289A (fr)
SE (1)	SE513082C2 (fr)
ZA (1)	ZA93686B (fr)

Families Citing this family (92)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20070117862A1 (en) *	1993-02-22	2007-05-24	Desai Neil P	Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6753006B1 (en)	1993-02-22	2004-06-22	American Bioscience, Inc.	Paclitaxel-containing formulations
US5886026A (en) *	1993-07-19	1999-03-23	Angiotech Pharmaceuticals Inc.	Anti-angiogenic compositions and methods of use
USRE38424E1 (en) *	1994-11-21	2004-02-10	The United States Of America As Represented By The Department Of Health And Human Services	Method for treating taxol side-effects with G-CSF
CN1304058C (zh)	1996-03-12	2007-03-14	Pg－Txl有限公司	水溶性紫杉醇产品
US6441025B2 (en) *	1996-03-12	2002-08-27	Pg-Txl Company, L.P.	Water soluble paclitaxel derivatives
US6515016B2 (en)	1996-12-02	2003-02-04	Angiotech Pharmaceuticals, Inc.	Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en)	1996-12-02	2002-12-17	Angiotech Pharmaceuticals, Inc.	Method for treating multiple sclerosis
US20030157187A1 (en) *	1996-12-02	2003-08-21	Angiotech Pharmaceuticals, Inc.	Compositions and methods for treating or preventing inflammatory diseases
US6458373B1 (en) *	1997-01-07	2002-10-01	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US20030105156A1 (en) *	1997-01-07	2003-06-05	Nagesh Palepu	Method for administration of a taxane/tocopherol formulation to enhance taxane therapeutic utility
US6727280B2 (en) *	1997-01-07	2004-04-27	Sonus Pharmaceuticals, Inc.	Method for treating colorectal carcinoma using a taxane/tocopherol formulation
US20030087954A1 (en) *	1997-01-07	2003-05-08	Sonus Pharmaceuticals, Inc.	Method of treating bladder carcinoma using a Taxane/Tocopherol formulation
GB9705903D0 (en)	1997-03-21	1997-05-07	Elliott Gillian D	VP22 Proteins and uses thereof
WO1998051369A1 (fr)	1997-05-13	1998-11-19	Edwards Stuart D	Dispositif et trousse pour traitement medical global
PT1023050E (pt) *	1997-06-27	2013-12-04	Abraxis Bioscience Llc	Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
EP2272504A3 (fr)	1997-06-27	2014-02-26	Abraxis BioScience, LLC	Nouvelles formulations d'agents pharmacologiques, leurs procédés de préparation et d'utilisation
HUP9701554D0 (en) *	1997-09-18	1997-11-28	Human Oltoanyagtermeloe Gyogys	Pharmaceutical composition containing plazma proteins
CA2298475A1 (fr) *	1997-10-31	1999-05-14	Walter Reed Army Institute Of Research	Procede permettant d'inhiber les effets secondaires de compositions pharmaceutiques contenant des excipients amphiphiles ou des molecules vecteurs de medicaments
TR200002299T2 (tr) *	1998-02-05	2000-11-21	Novartis Ag	Epotilon kompozisyonları.
US6683100B2 (en)	1999-01-19	2004-01-27	Novartis Ag	Organic compounds
US6194181B1 (en)	1998-02-19	2001-02-27	Novartis Ag	Fermentative preparation process for and crystal forms of cytostatics
US7030155B2 (en) *	1998-06-05	2006-04-18	Sonus Pharmaceuticals, Inc.	Emulsion vehicle for poorly soluble drugs
US6121029A (en)	1998-06-18	2000-09-19	Novartis Ag	Genes for the biosynthesis of epothilones
US7314637B1 (en)	1999-06-29	2008-01-01	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US6461637B1 (en) *	2000-09-01	2002-10-08	Neopharm, Inc.	Method of administering liposomal encapsulated taxane
US6017948A (en) *	1998-10-30	2000-01-25	Supergen, Inc.	Water-miscible pharmaceutical compositions
US6235776B1 (en) *	1998-11-12	2001-05-22	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
US6472420B2 (en) *	1998-11-12	2002-10-29	Cell Pathways, Inc.	Method for treating a patient with neoplasia by treatment with a paclitaxel derivative
JP2003501488A (ja) *	1999-06-11	2003-01-14	ネオルックスコーポレイション	骨髄抑制のための高投与量放射性核種錯体
TW422706B (en)	1999-07-01	2001-02-21	Wang Iz Rung	An oil-in-water emulsion type of paclitaxel
US7094885B2 (en) *	1999-07-11	2006-08-22	Neorx Corporation	Skeletal-targeted radiation to treat bone-associated pathologies
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
US20030054977A1 (en) *	1999-10-12	2003-03-20	Cell Therapeutics, Inc.	Manufacture of polyglutamate-therapeutic agent conjugates
US6136846A (en)	1999-10-25	2000-10-24	Supergen, Inc.	Formulation for paclitaxel
US6828346B2 (en) *	1999-10-25	2004-12-07	Supergen, Inc.	Methods for administration of paclitaxel
JP2001247459A (ja)	2000-03-03	2001-09-11	Oakland Uniservices Ltd	癌の組み合わせ療法
US20020077290A1 (en) *	2000-03-17	2002-06-20	Rama Bhatt	Polyglutamic acid-camptothecin conjugates and methods of preparation
AU2001253336A1 (en)	2000-04-10	2001-10-23	Teva Pharmaceutical Industries Ltd.	Method 0f administration of paclitaxel-plasma protein formulation
WO2002009700A1 (fr)	2000-07-28	2002-02-07	Cancer Research Technology Limited	Traitement combine contre le cancer
EP1390081A2 (fr)	2001-01-08	2004-02-25	Neorx Corporation	Composes, compositions et methodes therapeutiques et diagnostiques
AU2002249958B2 (en)	2001-01-16	2007-11-08	Vascular Therapies, Inc.	Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts
US7115565B2 (en)	2001-01-18	2006-10-03	Pharmacia & Upjohn Company	Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US6548531B2 (en)	2001-02-09	2003-04-15	Hoffmann-La Roche Inc.	Method for cancer therapy
US7666414B2 (en) *	2001-06-01	2010-02-23	Cornell Research Foundation, Inc.	Methods for treating prostate cancer using modified antibodies to prostate-specific membrane antigen
US7514078B2 (en)	2001-06-01	2009-04-07	Cornell Research Foundation, Inc.	Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
WO2002098897A2 (fr) *	2001-06-01	2002-12-12	Cornell Research Foundation, Inc.	Anticorps modifies diriges contre l'antigene prostatique specifique membranaire et utilisations associees
GB0121285D0 (en)	2001-09-03	2001-10-24	Cancer Res Ventures Ltd	Anti-cancer combinations
US20030054042A1 (en) *	2001-09-14	2003-03-20	Elaine Liversidge	Stabilization of chemical compounds using nanoparticulate formulations
WO2003026581A2 (fr) *	2001-09-26	2003-04-03	Intermune, Inc.	Compositions pharmaceutiques et methodes de traitement du cancer
CN1592607A (zh) *	2001-10-15	2005-03-09	克里蒂泰克公司	水溶性差药物的组合物、其给药方法和治疗方法
EP2316468A1 (fr)	2002-02-22	2011-05-04	Shire LLC	Système de distribution et méthodes de protection et d'administration de dextroamphetamine
US20080220075A1 (en) *	2002-03-20	2008-09-11	Elan Pharma International Ltd.	Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (fr) *	2002-03-20	2003-10-02	Elan Pharma International, Ltd.	Compositions nanoparticulaires d'inhibiteurs d'angiogenese
GB2386836B (en)	2002-03-22	2006-07-26	Cancer Res Ventures Ltd	Anti-cancer combinations
EP1496888A1 (fr) *	2002-04-12	2005-01-19	multimmune GmbH	Quantites non toxiques de substances entrainant l'agregation des proteines destinees a stimuler l'expression de hsp70 et a agir comme agents antitumoraux
AU2003239393A1 (en) *	2002-05-10	2003-11-11	Agennix Incorporated	Intratumorally administered lactoferrin in the treatment of malignant neoplasms and other hyperproliferative diseases
CZ294371B6 (cs) *	2002-06-10	2004-12-15	Pliva - Lachema, A. S.	Stabilizovaná farmaceutická kompozice na bázi polyoxyethylovaného ricinového oleje a způsob její přípravy
US20040047835A1 (en) *	2002-09-06	2004-03-11	Cell Therapeutics, Inc.	Combinatorial drug therapy using polymer drug conjugates
GB2394658A (en)	2002-11-01	2004-05-05	Cancer Rec Tech Ltd	Oral anti-cancer composition
BRPI0407096A (pt) *	2003-02-03	2006-01-24	Neopharm Inc	Taxano encapsulado em lipossomo estável, estéril e filtrável e outros fármacos antineoplásicos
WO2004080445A1 (fr) *	2003-03-12	2004-09-23	Molecular Engines Laboratories Sa	Methodes et compositions pour le traitement du cancer
US7085886B2 (en) *	2003-05-28	2006-08-01	International Buisness Machines Corporation	Autonomic power loss recovery for a multi-cluster storage sub-system
US20050208095A1 (en) *	2003-11-20	2005-09-22	Angiotech International Ag	Polymer compositions and methods for their use
WO2005094882A1 (fr) *	2004-03-03	2005-10-13	Millennium Pharmaceuticals, Inc.	Anticorps modifies diriges contre un antigene membranaire specifique de la prostate
US7989490B2 (en)	2004-06-02	2011-08-02	Cordis Corporation	Injectable formulations of taxanes for cad treatment
US8557861B2 (en) *	2004-09-28	2013-10-15	Mast Therapeutics, Inc.	Low oil emulsion compositions for delivering taxoids and other insoluble drugs
GB0501192D0 (en) *	2005-01-20	2005-03-02	Resolution Chemicals Ltd	Stable prostaglandin-containing compositions
KR20070114753A (ko)	2005-02-18	2007-12-04	아브락시스 바이오사이언스 인크.	치료제의 조합 및 투여 방식, 및 조합 요법
US8735394B2 (en)	2005-02-18	2014-05-27	Abraxis Bioscience, Llc	Combinations and modes of administration of therapeutic agents and combination therapy
US20070003557A1 (en) *	2005-04-21	2007-01-04	Andres Forero	Method for treating cancer using premedication
EP1896007B1 (fr)	2005-05-04	2014-03-19	Medigene AG	Methode d'administration d'une preparation liposomale cationique contenant du paclitaxel
TWI376239B (en) *	2006-02-01	2012-11-11	Andrew Xian Chen	Vitamin e succinate stabilized pharmaceutical compositions, methods for the preparation and the use thereof
WO2007109184A2 (fr) *	2006-03-16	2007-09-27	Bionumerik Pharmaceuticals, Inc.	Composés augmentant l'activité anticancéreuse, formulations les contenant et leurs méthodes d'utilisation
BRPI0709075A2 (pt)	2006-03-20	2011-10-11	Medigene Ag	tratamento de cáncer de mama triplo receptor negativo
CN101511372B (zh) *	2006-07-07	2011-11-16	蒂尔坦制药有限公司	包含h2-阻断剂、至少一种抗炎剂和细胞毒性剂的抗癌药物组合物
US8242165B2 (en) *	2006-10-26	2012-08-14	Creighton University	Mucoadhesive nanoparticles for cancer treatment
AU2008352597B2 (en)	2008-03-14	2012-03-08	Bionumerik Pharmaceuticals, Inc.	Treatment methods and compositions for lung cancer, adenocarcinoma, and other medical conditions
JP5667886B2 (ja)	2008-03-14	2015-02-12	バイオニューメリック・ファーマスーティカルズ・インコーポレイテッド	癌患者の生存時間を増大させるための組成物及び化合物の使用方法
MX2011009413A (es)	2009-03-11	2011-10-21	Ambit Biosciences Corp	Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
EP3141245A1 (fr)	2010-03-29	2017-03-15	Abraxis BioScience, LLC	Méthodes de traitement du cancer
MX2012011155A (es)	2010-03-29	2012-12-05	Abraxis Bioscience Llc	Metodos para mejorar suministros de farmacos y efectividad de agentes terapeuticos.
ES2993140T3 (en)	2010-04-02	2024-12-23	Amunix Pharmaceuticals Inc	Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
MX347225B (es)	2010-06-04	2017-04-19	Abraxis Bioscience Llc *	Metodos de tratamiento contra el cancer pancreatico.
AR099812A1 (es)	2014-03-21	2016-08-17	Abbvie Inc	Anticuerpos y conjugados de anticuerpo y fármaco anti-egfr
WO2017214322A1 (fr)	2016-06-08	2017-12-14	Abbvie Inc.	Anticorps anti-b7-h3 et conjugués anticorps-médicaments
US20200147235A1 (en)	2016-06-08	2020-05-14	Abbvie Inc.	Anti-cd98 antibodies and antibody drug conjugates
MX2018015285A (es)	2016-06-08	2019-09-18	Abbvie Inc	Anticuerpos anti-b7-h3 y conjugados de anticuerpo y farmaco.
AU2017279550A1 (en)	2016-06-08	2019-01-03	Abbvie Inc.	Anti-B7-H3 antibodies and antibody drug conjugates
JP2019524651A (ja)	2016-06-08	2019-09-05	アッヴィ・インコーポレイテッド	抗ｃｄ９８抗体及び抗体薬物コンジュゲート
US11154511B2 (en)	2016-09-29	2021-10-26	Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.	Albumin pharmaceutical composition and preparation method therefor
AR124681A1 (es)	2021-01-20	2023-04-26	Abbvie Inc	Conjugados anticuerpo-fármaco anti-egfr

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2601675B1 (fr) *	1986-07-17	1988-09-23	Rhone Poulenc Sante	Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
FR2629818B1 (fr) *	1988-04-06	1990-11-16	Centre Nat Rech Scient	Procede de preparation du taxol
WO1992019765A1 (fr) *	1991-05-08	1992-11-12	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	Procede de conception de traitements du cancer, procedes et compositions pharmaceutiques de traitements du cancer
FR2678833B1 (fr) *	1991-07-08	1995-04-07	Rhone Poulenc Rorer Sa	Nouvelles compositions pharmaceutiques a base de derives de la classe des taxanes.

1993
- 1993-01-07 CA CA002086874A patent/CA2086874E/fr not_active Expired - Fee Related
- 1993-01-29 AU AU32168/93A patent/AU3216893A/en not_active Abandoned
- 1993-01-29 NZ NZ245795A patent/NZ245795A/xx not_active IP Right Cessation
- 1993-01-29 AU AU32102/93A patent/AU641894B3/en not_active Ceased
- 1993-02-01 ZA ZA93686A patent/ZA93686B/xx unknown
- 1993-02-02 MY MYPI93000157A patent/MY109862A/en unknown
- 1993-06-02 IL IL10587993A patent/IL105879A/en not_active IP Right Cessation
- 1993-06-04 DK DK065293A patent/DK65293A/da not_active Application Discontinuation
- 1993-06-07 GB GB939311740A patent/GB9311740D0/en active Pending
- 1993-06-08 IE IE930433A patent/IE80620B1/en not_active IP Right Cessation
- 1993-06-08 SE SE9301951A patent/SE513082C2/sv not_active IP Right Cessation
- 1993-06-10 GR GR930100239A patent/GR1001617B/el not_active IP Right Cessation
- 1993-06-15 PT PT101289A patent/PT101289A/pt not_active Application Discontinuation
- 1993-06-22 NL NL9301086A patent/NL9301086A/nl not_active Application Discontinuation
- 1993-07-15 JP JP5174994A patent/JP2848760B2/ja not_active Expired - Lifetime
- 1993-07-19 ES ES09301618A patent/ES2105926B1/es not_active Expired - Fee Related
- 1993-07-29 IT IT93MI001714A patent/IT1276041B1/it active IP Right Grant
- 1993-07-29 EP EP97104511A patent/EP0783885A3/fr not_active Withdrawn
- 1993-07-29 EP EP93401978A patent/EP0584001B1/fr not_active Revoked
- 1993-07-29 FR FR9309372A patent/FR2694192B1/fr not_active Expired - Fee Related
- 1993-07-29 DK DK93401978.7T patent/DK0584001T3/da active
- 1993-07-29 EP EP97104512A patent/EP0783886A3/fr not_active Withdrawn
- 1993-07-29 AT AT93401978T patent/ATE152910T1/de not_active IP Right Cessation
- 1993-07-29 ES ES93401978T patent/ES2101261T3/es not_active Expired - Lifetime
- 1993-07-29 DE DE69310634T patent/DE69310634T2/de not_active Revoked
- 1993-07-30 BE BE9300800A patent/BE1006497A5/fr active
- 1993-08-02 DE DE4325927A patent/DE4325927B4/de not_active Revoked
- 1993-08-03 CH CH02325/93A patent/CH686868A5/de not_active IP Right Cessation
1995
- 1995-10-18 US US08/544,594 patent/US5641803A/en not_active Expired - Lifetime
- 1995-11-20 US US08/559,890 patent/US5621001A/en not_active Expired - Lifetime
1996
- 1996-01-19 AU AU42070/96A patent/AU704393C/en not_active Ceased
- 1996-09-19 US US08/715,914 patent/US5670537A/en not_active Expired - Lifetime
- 1996-11-22 US US08/755,740 patent/US5665761A/en not_active Expired - Lifetime
1997
- 1997-08-13 GR GR970402058T patent/GR3024415T3/el unknown
2000
- 2000-02-07 US US09/499,373 patent/US6414014B1/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
EP0584001B1 (fr)	1997-05-14
EP0584001A1 (fr)	1994-02-23
FR2694192B1 (fr)	1995-01-27
CH686868A5 (de)	1996-07-31
EP0783886A3 (fr)	1997-07-23
DE69310634D1 (de)	1997-06-19
DK65293A (da)	1994-02-04
ITMI931714A0 (it)	1993-07-29
US6414014B1 (en)	2002-07-02
ES2101261T3 (es)	1997-07-01
EP0783885A2 (fr)	1997-07-16
SE9301951D0 (sv)	1993-06-08
ZA93686B (en)	1993-09-06
IT1276041B1 (it)	1997-10-24
ES2105926A1 (es)	1997-10-16
CA2086874A1 (fr)	1994-02-04
JPH07233064A (ja)	1995-09-05
JP2848760B2 (ja)	1999-01-20
NL9301086A (nl)	1994-03-01
GR3024415T3 (en)	1997-11-28
IE80620B1 (en)	1998-10-21
IE930433A1 (en)	1994-02-09
ITMI931714A1 (it)	1995-01-29
DE4325927B4 (de)	2004-04-15
EP0783886A2 (fr)	1997-07-16
GB9311740D0 (en)	1993-07-21
CA2086874E (fr)	2000-01-04
US5670537A (en)	1997-09-23
AU3216893A (en)	1994-02-10
ATE152910T1 (de)	1997-05-15
DE4325927A1 (de)	1994-03-10
US5641803A (en)	1997-06-24
DK0584001T3 (da)	1997-08-25
DK65293D0 (da)	1993-06-04
GR1001617B (el)	1994-07-29
EP0783885A3 (fr)	1997-08-06
IL105879A0 (en)	1993-10-20
CA2086874C (fr)	1998-09-01
ES2105926B1 (es)	1998-07-01
BE1006497A5 (fr)	1994-09-13
US5665761A (en)	1997-09-09
PT101289A (pt)	1994-04-29
AU704393C (en)	2002-07-25
US5621001A (en)	1997-04-15
MY109862A (en)	1997-09-30
SE9301951L (sv)	1994-02-07
AU704393B2 (en)	1999-04-22
FR2694192A1 (fr)	1994-02-04
IL105879A (en)	1998-08-16
DE69310634T2 (de)	1998-01-02
AU641894B3 (en)	1993-09-30
AU4207096A (en)	1996-04-26
NZ245795A (en)	1999-05-28

Legal Events

Date	Code	Title	Description
2009-02-17	NUG	Patent has lapsed

Publication	Publication Date	Title
SE513082C2 (sv)	2000-07-03	Användning av taxol i infusionspreparat
CN105705148B (zh)	2021-03-23	使用普那布林和紫杉烷的组合的癌症疗法
MX2008008723A (es)	2008-09-26	Tratamiento de la hepatitis viral.
Palumbo et al.	2012	How to manage neutropenia in multiple myeloma
US20260053791A1 (en)	2026-02-26	Use of tivozanib to treat subjects with refractory cancer
JPS59112948A (ja)	1984-06-29	コレステロ−ルレベル低下剤
CN103370066A (zh)	2013-10-23	用于治疗癌症的包含威罗菲尼和干扰素的组合疗法
CN105813637A (zh)	2016-07-27	用于治疗慢性疲劳综合征的可溶性鸟苷酸环化酶的激活剂或刺激剂
CN117797149A (zh)	2024-04-02	西达本胺联合r-chop的应用及联合药物
Porter et al.	2023	Iron chelation
CN119894507A (zh)	2025-04-25	嵌合抗原受体（car）t细胞辅助疗法
CN114028374A (zh)	2022-02-11	富马酸二甲酯在制备用于保护胰岛β细胞功能的药物中的用途
GB2269319A (en)	1994-02-09	Compositions containing taxol
HK1001199A (en)	1998-06-05	Use of taxol for the manufacture of a medicament for the treatment of cancer
HK1001200A (en)	1998-06-05	Use of taxol for the manufacture of a medicament for the treatment of cancer
Legnani et al.	2004	Newer therapies for inflammatory bowel disease
WO2025209478A1 (fr)	2025-10-09	Méthodes de traitement de l'anémie hémolytique auto-immune à anticorps chauds faisant appel au sovléplénib
AU7179200A (en)	2001-02-08	Method of treatment of breast cancer
WO2024158001A1 (fr)	2024-08-02	Méthode de traitement du lymphome b canin
WO2026046429A1 (fr)	2026-03-05	Utilisation d'une monothérapie à base d'olmésartan médoxomil et d'une polythérapie associée avec du sorafénib pour prévention/traitement de diabète
Dittrich et al.	2000	Therapy of the small cell lung cancer—Comparison two established chemotherapy regime (ACO vs. CEV)
JPH0867637A (ja)	1996-03-12	肝疾患予防治療薬
WO2013019222A1 (fr)	2013-02-07	Compositions et procédés de traitement du syndrome myélodysplasique
HK1185808B (en)	2016-09-02	Combination therapy comprising vemurafenib and an interferon for use in the treatment of cancer